Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Galactomannan detection for invasive aspergillosis in immunocompromized patients

Esta versión no es la más reciente

Información

DOI:
https://doi.org/10.1002/14651858.CD007394Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 07 octubre 2008see what's new
Tipo:
  1. Diagnostic
Etapa:
  1. Review
Grupo Editorial Cochrane:
  1. Grupo Cochrane de Vías respiratorias

Copyright:
  1. Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Mariska M. Leeflang

    Correspondencia a: Department of Clinical Epidemiology and Biostatistics, Academic Medical Center, J1B‐210, AMSTERDAM, Netherlands

    [email protected]

  • Yvette J Debets‐Ossenkopp

    Department of Clinical Microbiology and Infection Control, VU Medical Centre, Free University, Amsterdam, Netherlands

  • Caroline E Visser

    Department of Medical Microbiology, Academic Medical Centre, University of Amsterdam, Amsterdam, Netherlands

  • Rob JPM Scholten

    Dutch Cochrane Centre, Academic Medical Center, Amsterdam, Netherlands

  • Lotty Hooft

    Dutch Cochrane Centre, Academic Medical Center, Amsterdam, Netherlands

  • Henk A Bijlmer

    Department of Clinical Microbiology and Infection Control, Bronovo hospital, The Hague, Netherlands

  • Johannes B Reitsma

    Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, Amsterdam, Netherlands

  • Patrick MM Bossuyt

    Department of Clinical Epidemiology and Biostatistics, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands

  • Christina M Vandenbroucke‐Grauls

    Department of Clinical Microbiology and Infection Control, VU Medical Centre, Free University, Amsterdam, Netherlands

Contributions of authors

ML: draft protocol; Searches; Study selection and data‐extraction; Analyses; draft review.

YD: study selection and data‐extraction; commented on protocol and review.

CV: study selection and data‐extraction; commented on protocol and review.

HB: data‐extraction; commented on protocol and review.

LH: data‐extraction; commented on protocol and review.

RS: data‐extraction; commented on protocol and review.

JBR: data‐analysis; commented on review.

PMB: commented on protocol and review.

CVG: initiator; Commented on protocol and review.

Declarations of interest

All authors state no conflicts of interest.

Acknowledgements

No acknowledgements.

Version history

Published

Title

Stage

Authors

Version

2015 Dec 30

Galactomannan detection for invasive aspergillosis in immunocompromised patients

Review

Mariska MG Leeflang, Yvette J Debets‐Ossenkopp, Junfeng Wang, Caroline E Visser, Rob JPM Scholten, Lotty Hooft, Henk A Bijlmer, Johannes B Reitsma, Mingming Zhang, Patrick MM Bossuyt, Christina M Vandenbroucke‐Grauls

https://doi.org/10.1002/14651858.CD007394.pub2

2008 Oct 07

Galactomannan detection for invasive aspergillosis in immunocompromized patients

Review

Mariska M. Leeflang, Yvette J Debets‐Ossenkopp, Caroline E Visser, Rob JPM Scholten, Lotty Hooft, Henk A Bijlmer, Johannes B Reitsma, Patrick MM Bossuyt, Christina M Vandenbroucke‐Grauls

https://doi.org/10.1002/14651858.CD007394

Differences between protocol and review

DRAFT Changes between Protocol and review

 

We stated we would contact authors and industry and this has not yet been done. This is now stated in the 'Methods' section.

We limited the accepted reference standard to EORTC(‐like) criteria. We originally stated it would be either autopsy, combined with a positive culture or with histopathological evidence, or the EORTC/MSG criteria, or the demonstration of hyphal invasion in biopsies, combined with a positive culture. The rationale for this is that autopsy is almost never done and that biopsy and culture are included in the EORTC/MSG criteria.

Items 2, 8 and 9 of the QUADAS‐checklist, as mentioned in the protocol and in the 'Methods' section, were reported in the 'Characteristics of included studies' table and not in the 'Assessment of methodological quality' table.

We did not calculate Likelihood Ratios and Odds Ratios, as described in the protocol, the reason for this is that we think that the value of this test is better described by explaining the consequences of false positive (1‐specificity) and false negative (1‐sensitivity) results.

Some extra explanation about independence of index and reference tests was added to the Methodology section (under ‘Assessment of Methodological Quality’).

In the protocol we stated that we would investigate the effect of: cut‐off values, reference standard, distinctive groups of patients, children versus adults, and use of antifungal therapy. In the review we did investigate the effects of: cut‐off values, reference standard and clinical subgroups (children versus adults; distinctive groups of patients (high risk versus low risk); use of antifungal prophylaxis; use of antifungal therapy).

In the protocol we stated that the main purpose for a test for invasive aspergillosis would be to guide therapy. During the review process, we discovered that the test is used in many different ways and in most studies it is not used to guide therapy (although a test that could guide therapy would still be ideal). We have therefore changed the text in such a way that there is less focus on guidance of therapy.

Notes

No published notes.